Vanguard Group
YMAB

Vanguard Group’s Y-mAbs Therapeutics YMAB Stock Holding History

Vanguard Group’s Portfolio YMAB Stock Details YMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-1,943,285
Closed -$8.76M – 4435
2025
Q2 		$8.76M Sell
1,943,285
-3,224
-0.2% -$14.5K ﹤0.01% 2975
2025
Q1 		$8.62M Sell
1,946,509
-53,513
-3% -$311K ﹤0.01% 2925
2024
Q4 		$15.7M Sell
2,000,022
-35,341
-2% -$430K ﹤0.01% 2707
2024
Q3 		$26.8M Buy
2,035,363
+78,024
+4% +$989K ﹤0.01% 2453
2024
Q2 		$23.6M Sell
1,957,339
-112,178
-5% -$1.51M ﹤0.01% 2484
2024
Q1 		$33.7M Sell
2,069,517
-174,721
-8% -$2.35M ﹤0.01% 2344
2023
Q4 		$15.3M Buy
2,244,238
+12,330
+0.6% +$71.3K ﹤0.01% 2714
2023
Q3 		$12.2M Buy
2,231,908
+4,899
+0.2% +$28.5K ﹤0.01% 2771
2023
Q2 		$15.1M Sell
2,227,009
-53,993
-2% -$405K ﹤0.01% 2714
2023
Q1 		$11.4M Buy
2,281,002
+22,748
+1% +$92.9K ﹤0.01% 2868
2022
Q4 		$11M Buy
2,258,254
+337,833
+18% +$2.45M ﹤0.01% 2913
2022
Q3 		$27.7M Sell
1,920,421
-9,495
-0.5% -$157K ﹤0.01% 2483
2022
Q2 		$29.2M Buy
1,929,916
+135,406
+8% +$1.58M ﹤0.01% 2457
2022
Q1 		$21.3M Sell
1,794,510
-22,564
-1% -$232K ﹤0.01% 2737
2021
Q4 		$29.5M Buy
1,817,074
+13,150
+0.7% +$281K ﹤0.01% 2639
2021
Q3 		$51.5M Buy
1,803,924
+168,669
+10% +$5.32M ﹤0.01% 2348
2021
Q2 		$55.3M Buy
1,635,255
+36,676
+2% +$1.18M ﹤0.01% 2315
2021
Q1 		$48.3M Buy
1,598,579
+117,546
+8% +$4.82M ﹤0.01% 2336
2020
Q4 		$73.3M Buy
1,481,033
+236,743
+19% +$11M ﹤0.01% 1998
2020
Q3 		$47.8M Buy
1,244,290
+4,626
+0.4% +$184K ﹤0.01% 2036
2020
Q2 		$53.6M Buy
1,239,664
+158,006
+15% +$5.98M ﹤0.01% 1980
2020
Q1 		$28.2M Buy
1,081,658
+26,461
+3% +$768K ﹤0.01% 2128
2019
Q4 		$33M Buy
1,055,197
+312,215
+42% +$9.24M ﹤0.01% 2301
2019
Q3 		$19.4M Buy
742,982
+253,400
+52% +$6.47M ﹤0.01% 2504
2019
Q2 		$11.2M Buy
489,582
+205,021
+72% +$4.71M ﹤0.01% 2796
2019
Q1 		$7.46M Buy
284,561
+27,296
+11% +$599K ﹤0.01% 2978
2018
Q4 		$5.23M Buy
257,265
+172,165
+202% +$3.95M ﹤0.01% 3071
2018
Q3 		$2.26M Buy
+85,100
New +$2.16M ﹤0.01% 3487

Other funds holding YMAB

BIG
Brooklyn Investment Group Brooklyn, New York $3.2B AUM 26.32% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return

Vanguard Group's YMAB Position: Q3 2025 in Review

Vanguard Group sold out of Y-mAbs Therapeutics (YMAB) in Q3 2025, closing a stake of 1,943,285 shares — an estimated $8.76M sold.

Vanguard Group first reported a position in YMAB in Q3 2018 and held it in 28 quarters. The position peaked at $73.3M in Q4 2020. 2 funds tracked by Wall St. Rank hold YMAB as of Q3 2025.

  • Vanguard Group reported no remaining Y-mAbs Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Vanguard Group sold 1,943,285 Y-mAbs Therapeutics shares in Q3 2025, an estimated $8.76M.
  • Vanguard Group first reported a position in Y-mAbs Therapeutics in Q3 2018 and held it in 28 quarters.
  • Vanguard Group's Y-mAbs Therapeutics position peaked at $73.3M in Q4 2020.
  • 2 funds tracked by Wall St. Rank held Y-mAbs Therapeutics as of Q3 2025.

Based on Vanguard Group's 13F filing for Q3 2025, filed 7 Nov 2025.